Scott Lyman
Chief Executive Officer and Chairman of the Board
Scott Lyman is the CEO and a Co-Founder of Belhaven Biopharma and serves as Chairman of the Board. Prior to founding Belhaven, he was the Chief Business Officer of Grid Therapeutics, a spinout from Duke University. Scott has previously held leadership roles at GSK, BioCryst, and Salix. His prior experience includes developing spray dried powders, leading drug development teams, participating in FDA filings, and the licensing of multiple products. In these roles, Scott contributed to the approvals of new Enbrel dosage forms, epilepsy medicine Ezogabine, antibiotic Xifaxan, and HIV medicine Tivicay.
Mr. Lyman holds a BS in Chemical Engineering from Iowa State University, a MS in Chemical Engineering from the University of Colorado at Boulder, and an MBA from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill.